Stock CLEVELAND BIOLABS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights Cleveland BioLabs, Inc. Nasdaq

Equities

US1858601032

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Cleveland BioLabs, Inc.
2021 Cleveland Biolabs : Cytocom Changing Name to Statera BioPharma MT
2021 Cleveland Biolabs, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cleveland Biolabs, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
Cleveland Biolabs : Cytocom Enters Research Collaboration Agreement With La Jolla Institute for Immunology
MT
Cleveland BioLabs : Cytocom Inc. Announces Completed Merger with Cleveland BioLabs (Form 8-K)
PU
Cytocom, Inc. completed the acquisition of Cleveland BioLabs, Inc. in a reverse merger transaction.
CI
Cytocom, Inc. completed the acquisition of Cleveland BioLabs, Inc. in a reverse merger transaction.
CI
Cleveland BioLabs : and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger
PR
Cleveland BioLabs : and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
PR
Cleveland Biolabs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Cleveland Biolabs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Cleveland BioLabs, Inc. Provides Earnings Guidance for the Year Ended December 31, 2020
CI
Cleveland Biolabs, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
CI
Cleveland BioLabs : Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement
PU
CLEVELAND BIOLABS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cleveland BioLabs, Inc. - CBLI
BU
CLEVELAND BIOLABS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cleveland BioLabs, Inc. - CBLI
BU
Cytocom, Inc. entered into an agreement to acquire Cleveland BioLabs, Inc. for $60.7 million in a reverse merger transaction.
CI
Cleveland Biolabs, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
CI
Cleveland BioLabs Intends to Seek Acquisition
CI
Cleveland Biolabs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
CI
Cleveland Biolabs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
CI
Cleveland Biolabs, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STAB Stock
  4. Stock
  5. News Cleveland BioLabs, Inc.
  6. Highlights